A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone

Clinical Trial ID NCT00295633

PubWeight™ 11.56^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00295633

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.	J Clin Endocrinol Metab	2009	1.44
2	Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.	BMJ	2016	1.21
3	Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.	Diab Vasc Dis Res	2011	1.06
4	Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination.	Patient Prefer Adherence	2014	0.91
5	Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials.	Cardiovasc Diabetol	2014	0.87
6	Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials.	Sci Rep	2016	0.85
7	Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus.	Clin Interv Aging	2013	0.83
8	Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.	Adv Ther	2015	0.77
9	Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.	Postgrad Med	2011	0.77
10	Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥ 65 years) with type 2 diabetes.	Clin Interv Aging	2014	0.77
11	Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease.	Vasc Health Risk Manag	2014	0.76
12	Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment.	Diabetes Ther	2016	0.75
13	Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin.	Int J Clin Pract	2013	0.75
14	A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.	Nutr Metab Cardiovasc Dis	2015	0.75